Estimating Interpretable Heterogeneous Treatment Effect with Causal Subgroup Discovery in Survival Outcomes (2409.19241v2)

Abstract: Estimating heterogeneous treatment effect (HTE) for survival outcomes has gained increasing attention, as it captures the variation in treatment efficacy across patients or subgroups in delaying disease progression. However, most existing methods focus on post-hoc subgroup identification rather than simultaneously estimating HTE and selecting relevant subgroups. In this paper, we propose an interpretable HTE estimation framework that integrates three meta-learners that simultaneously estimate CATE for survival outcomes and identify predictive subgroups. We evaluated the performance of our method through comprehensive simulation studies across various randomized clinical trial (RCT) settings. Additionally, we demonstrated its application in a large RCT for age-related macular degeneration (AMD), a polygenic progressive eye disease, to estimate the HTE of an antioxidant and mineral supplement on time-to-AMD progression and to identify genetics-based subgroups with enhanced treatment effects. Our method offers a direct interpretation of the estimated HTE and provides evidence to support precision healthcare.